IP Library Granted Patent US 10,010,568
Granted Patent B2
US 10,010,568 · App. 15/342,642 · Granted Jul 3, 2018

Method and system for reducing the likelihood of a spirochetes infection in a human being

Inventors: Katherine Rose Kovarik (Englewood, CO); Joseph E. Kovarik (Englewood, CO)
A61K35/74A61C19/066A61K9/006A61K9/007A61K9/0034A61K9/0043A61K9/0063A61K31/4704A61K31/519A61K31/65A61K35/741A61K35/742A61K35/745A61K35/747A61K39/0007A61K39/0008A61K45/06A61K2039/58
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,010,568
App. No.
15/342,642
Granted
Jul 3, 2018
Kind
B2
Abstract

A method and system of reducing the likelihood of an inflammatory disease developing by providing a mucosal adhesive strip to a subject, with the strip provided with at least one of a plurality of agents effective to hinder the growth of spirochetes bacteria in a subject's oral cavity. In certain embodiments, an effective amount of Prevotella intermedia is provided to decrease the incidence of periodontitis and to reduce the progression of Alzheimer's disease. In still other embodiments, the likelihood that a subject will suffer from Alzheimer's disease is reduced by administering via local gingival application to a subject that has been diagnosed with periodontitis an effective amount of an antibiotic effective to kill spirochetes bacteria residing on the subgingival tooth area of the subject.

Claims (13)

1. A method of reducing the likelihood of a Treponema spirochete infection in a human being, comprising, providing a bioadhesive strip to a human being who has been diagnosed with periodontitis, said strip adapted to bind to a mucosal membrane of said human being, the strip having a first and second side, the first side having a bioadhesive that is adapted to bind to a mucosal membrane for at least 1 hour while inside a person's mouth, wherein said strip comprises a polymer, and between 0.2 and 0.9% xylitol by weight, and a therapeutically effective amount of an anti-biofilm agent, and an antibiotic comprising at least one of methotrexate and paquinimod, in an amount effective to inhibit collagenase activity.

2. The method as set forth in claim 1 , further comprising orally administering to the subgingival tooth area of the human being a second antibiotic in an effective amount to kill Treponema spirochetes bacteria residing on the subgingival tooth area of the human being wherein said antibiotic comprises one of azithromycin and ceftriaxone.

3. The method as set forth in claim 1 , wherein said strip comprises bioluminescent material.

4. The method as set forth in claim 1 , wherein said strip comprises compounds that facilitate the growth of desired bacteria beneficial to a person's health.

5. A method of reducing the likelihood of a Treponema spirochete infection in a human being, comprising,

providing a bioadhesive strip to a human being who has been diagnosed with periodontitis, wherein said strip has a first and second side, the first side having a bioadhesive that is adapted to bind to a mucosal membrane for at least 3 hours while inside a person's mouth, said strip being devoid of manganese and copper, wherein said strip includes at least about 200 mg xylitol and an effective amount of paquinimod to inhibit collagenase activity.

6. The method as set forth in claim 5 , further comprising orally administering to the subgingival tooth area of the human being a second antibiotic in an effective amount to kill Treponema spirochetes bacteria residing on the subgingival tooth area of the human being, wherein said antibiotic comprises one of methotrexate, azithromycin and ceftriaxone.

7. The method as set forth in claim 5 , wherein said strip includes between 0.2 and 0.9% xylitol by weight.

8. The method as set forth in claim 5 , wherein said strip comprises bioluminescent material.

9. The method as set forth in claim 5 , wherein said strip has a surface topography for resisting bioadhesion and a pattern defined by a plurality of spaced apart features attached to or projected into a base surface, said plurality of features each having at least one microscale dimension and having at least one neighboring feature having a substantially different geometry, wherein an average spacing between adjacent ones of said features is between 0.5 and 5 microns.

10. A method of reducing the likelihood of a Treponema spirochete infection in a human being, comprising,

providing a bioadhesive strip to a human being who has been diagnosed with periodontitis, wherein said strip has a first and second side, the first side having a bioadhesive that is adapted to bind to a mucosal membrane for at least 3 hours while inside a person's mouth, said strip being devoid of manganese and copper, wherein said strip includes at least about 200 mg xylitol and an effective amount of an antibiotic effective to kill spirochetes bacteria residing on the subgingival tooth area of the human being, wherein said antibiotic is selected from the group consisting of methotrexate, azithromycin and ceftriaxone.

11. The method as set forth in claim 10 , wherein said strip has a surface topography for resisting bioadhesion and a pattern defined by a plurality of spaced apart features attached to or projected into a base surface, said plurality of features each having at least one microscale dimension and having at least one neighboring feature having a substantially different geometry, wherein an average spacing between adjacent ones of said features is between 0.5 and 5 microns.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2022
From: KOVARIK, JOE
To: SEED HEALTH, INC.
Reel/Frame 059690/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2021
From: KOVARIK, JOSEPH E
To: KOVARIK, JOSEPH E.
Reel/Frame 057819/0661 →
Continuity (16)
Continuation In Part 15270034 · Sep 20, 2016
Continuation In Part 14954074 · Nov 30, 2015
Continuation In Part 14574517 · Dec 18, 2014
Continuation In Part 15342642
Continuation In Part 15228454 · Aug 4, 2016
Continuation In Part 14752192 · Jun 26, 2015
Continuation In Part 14225503 · Mar 26, 2014
Continuation 13367052 · Feb 6, 2012
Provisional Application 62260906 · Nov 30, 2015
Provisional Application 62072476 · Oct 30, 2014
Provisional Application 62053926 · Sep 23, 2014
Provisional Application 62014855 · Jun 20, 2014
Provisional Application 61919297 · Dec 20, 2013
Provisional Application 61556023 · Nov 4, 2011
Provisional Application 61439652 · Feb 4, 2011
Related Publication 20170071986A1 · Mar 16, 2017
Cited By (1)
US 12,318,377